Wutah bathi EPS kuartalan kamada.com (KMDA)

The history of quarterly earnings per share changes confirms the pricing power of Kamada Ltd. (KMDA) due to the indispensability of the drug Glassia. High business margins are based on exclusive plasma protein purification methods. Meanwhile, the 51.20 indicator reflects the status of current yields. Growth prospects rely on the systematic development of the R&D pipeline and the introduction of new inhalation therapy forms.

To diversify the portfolio with high-quality assets, I prioritize cash flow stability. This indicator measures the percentage deviation of current net earnings per share from the value of the same quarter last year. This trend confirms the operational resilience of Kamada Ltd. (KMDA) management during its expansion into the US market. By analyzing the quarterly change in earnings per share, an investor can identify the risk of a "value trap." The positive trend on this chart signals an increase in business margins.